
|Articles|June 1, 2016
- Pharmaceutical Executive-06-01-2016
- Volume 36
- Issue 6
Pharmaceutical Executive, June 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive June 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 9 years ago
Pharm Exec's Top 50 Companies 2016over 9 years ago
Diversity and Inclusion: A Pharma 50 Perspectiveover 9 years ago
Design that Deliversover 9 years ago
A Digital Prescription for the Pharma Industryover 9 years ago
Science Meets Art: Mapping the Topography of MSover 9 years ago
Pharma and Biotech Financial Outlook: Hazyover 9 years ago
Promises and Pitfalls in Calculating Drug Valueover 9 years ago
Europe’s ‘Radical’ Regulators Drawn Further into Pricing Debateover 9 years ago
Country Report: ItalyNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan
2
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
3
Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026
4
FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices
5




